It is not true that regulators failed to monitor cancer risks after the rollout of COVID-19 mRNA vaccines. Regulatory agencies, such as the FDA (U.S.), MHRA (UK), EMA (EU), and TGA (Australia), have continuously monitored vaccine safety, including potential links to cancer.
How Cancer Risks Were Monitored:
1. Clinical Trials:
• Before approval, mRNA vaccines underwent large clinical trials with tens of thousands of participants. No cancer risk was identified.
2. Post-Marketing Surveillance:
• Governments and independent researchers used real-world data from millions of vaccinated people.
• VAERS (U.S.), Yellow Card (UK), EudraVigilance (EU), and other databases track adverse events, including cancers.
3. Cancer Registries & Epidemiological Studies:
• Cancer rates continue to be tracked by national cancer registries worldwide.
• No increase in aggressive cancers linked to vaccines has been found in peer-reviewed studies.
4. Independent Studies:
• Multiple studies have examined whether mRNA vaccines affect cancer rates.
• No causal link between vaccination and increased cancer incidence has been found.
Key Takeaway:
Regulatory agencies did monitor cancer risks and continue to do so. Claims that they ignored potential cancer concerns are not supported by evidence.